Medico Remedies Ltd. (IN:MEDICO)
:MEDICO
Want to see IN:MEDICO full AI Analyst Report?
MEDICO Stock Chart & Stats
₹50.16
₹4.58(8.10%)
At close: 4:00 PM EST
₹50.16
₹4.58(8.10%)
Day’s Range― - ―
52-Week Range₹31.00 - ₹56.99
Previous CloseN/A
Volume2.72M
Average Volume (3M)12.74K
Market Cap
₹3.53B
Enterprise Value₹3.74B
Total Cash (Recent Filing)₹17.64M
Total Debt (Recent Filing)₹125.27M
Price to Earnings (P/E)27.1
Beta0.13
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.37
Shares Outstanding82,984,000
10 Day Avg. Volume20,955
30 Day Avg. Volume12,740
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)3.60
Price to Sales (P/S)1.32
P/FCF Ratio-78.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent top-line expansion, accelerating to ~20% in FY2026, indicates durable demand and successful commercial execution. Over a 2–6 month horizon this supports market position, scale benefits and the ability to invest in capacity or R&D, strengthening long-term growth prospects.
Healthy Balance Sheet And Improving LeverageRising equity and materially improved leverage provide a durable financial buffer, enabling investment and resilience through industry cycles. A stronger capital base improves access to financing on better terms and reduces insolvency risk over the medium term.
Improving Profitability And ReturnsMaterial improvement in net income and stable ROE (~16%) reflect efficient capital deployment and operational leverage. Persistent profitability supports reinvestment, debt service and shareholder value creation, making earnings sustainability a positive structural attribute.
Bears Say
Weak Cash Conversion And Negative Free Cash FlowVolatile and deteriorating cash conversion is a structural concern: earnings are not translating reliably into cash, and negative FCF constrains organic funding for capex, acquisitions or dividends. This increases reliance on external financing and raises medium-term execution risk.
Margin VolatilitySignificant swings in gross and operating margins indicate exposure to pricing, input-cost or product-mix pressures. Margin instability reduces predictability of profits and undermines planning for investment and pricing strategies, elevating execution risk over coming quarters.
Recent Uptick In BorrowingsDebt increase during a period of weak cash conversion raises structural leverage risk. Higher borrowings can strain interest coverage and limit flexibility for capital allocation, especially if operating cash flow remains volatile and free cash flow stays negative.
Medico Remedies Ltd. News
MEDICO FAQ
What was Medico Remedies Ltd.’s price range in the past 12 months?
Medico Remedies Ltd. lowest stock price was ₹31.00 and its highest was ₹56.99 in the past 12 months.
What is Medico Remedies Ltd.’s market cap?
Medico Remedies Ltd.’s market cap is ₹3.53B.
When is Medico Remedies Ltd.’s upcoming earnings report date?
Medico Remedies Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 45 days.
How were Medico Remedies Ltd.’s earnings last quarter?
Medico Remedies Ltd. released its earnings results on May 21, 2026. The company reported ₹0.71 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.71.
Is Medico Remedies Ltd. overvalued?
According to Wall Street analysts Medico Remedies Ltd.’s price is currently Overvalued.
Does Medico Remedies Ltd. pay dividends?
Medico Remedies Ltd. does not currently pay dividends.
What is Medico Remedies Ltd.’s EPS estimate?
Medico Remedies Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medico Remedies Ltd. have?
Medico Remedies Ltd. has 82,984,000 shares outstanding.
What happened to Medico Remedies Ltd.’s price movement after its last earnings report?
Medico Remedies Ltd. reported an EPS of ₹0.71 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.041%.
Which hedge fund is a major shareholder of Medico Remedies Ltd.?
Currently, no hedge funds are holding shares in IN:MEDICO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medico Remedies Ltd.
Medico Remedies Limited is an India-based pharmaceutical firm dedicated to the manufacturing and sale of a diverse range of allopathic medicinal products. The company's comprehensive product lineup spans numerous therapeutic areas, including anti-infectives (such as antibiotics, beta-lactams, penicillins, cephalosporins, and antifungals), cardiovascular medications, and pain and fever management drugs like antipyretics, analgesics, and NSAIDs. Additionally, Medico Remedies produces treatments for gastrointestinal conditions (antacids, anti-ulcerants), neurological and psychiatric disorders (antidepressants, anti-epileptics, antipsychotics), and antimalarial drugs. Their offerings also include vitamins and supplements, anti-diabetics, and various formulations such as syrups, dry syrups, ointments, and creams. Beyond its substantial presence in the Indian market, the company also engages in international trade, exporting its pharmaceuticals to nations like Kazakhstan, Kyrgyzstan, Botswana, Jamaica, and Niger. Medico Remedies Limited was founded in 1994 and is headquartered in Mumbai, India.
Technical Analysis
Albert David Ltd
―
Bafna Pharmaceuticals Limited
―
Medicamen Biotech Limited
―
Valiant Laboratories Ltd.
―
Zim Laboratories Ltd.
―